EcoDrugPlus

Sigma Non-Opioid Intracellular Receptor 1

Ensembl ID : ENSLCRG00005002203
Gene Symbol: SIGMAR1
3 Cross references
204 Possible Orthologues:

Smoothened, Frizzled Class Receptor

Ensembl ID : ENSLCRG00005019733
Gene Symbol: SMO
3 Cross references
204 Possible Orthologues:

Sodium Channel Protein Type 4 Subunit Alpha

Ensembl ID : ENSLCRG00005008654
Gene Symbol: LOC104932209
3 Cross references
262 Possible Orthologues:

Sodium Channel, Voltage Gated, Type Xii, Alpha A

Ensembl ID : ENSLCRG00005016742
Gene Symbol: SCN12AA
3 Cross references
248 Possible Orthologues:

Sodium Voltage-Gated Channel Alpha Subunit 4

Ensembl ID : ENSLCRG00005021802
Gene Symbol: SCN4A
3 Cross references
191 Possible Orthologues:

Sodium Voltage-Gated Channel Alpha Subunit 8

Ensembl ID : ENSLCRG00005008090
Gene Symbol: SCN8A
3 Cross references
215 Possible Orthologues:

Sodium Voltage-Gated Channel Alpha Subunit 8

Ensembl ID : ENSLCRG00005007553
Gene Symbol: SCN8A
3 Cross references
216 Possible Orthologues:

Sodium/potassium-Transporting Atpase Subunit Alpha-1

Ensembl ID : ENSLCRG00005002126
Gene Symbol: LOC104928331
3 Cross references
181 Possible Orthologues:

Solute Carrier Family 10 Member 2

Ensembl ID : ENSLCRG00005001550
Gene Symbol: SLC10A2
3 Cross references
214 Possible Orthologues:

Solute Carrier Family 18 Member 2

Ensembl ID : ENSLCRG00005012637
Gene Symbol: SLC18A2
3 Cross references
216 Possible Orthologues:

Solute Carrier Family 22 Member 6, Like

Ensembl ID : ENSLCRG00005009954
Gene Symbol: SLC22A6L
3 Cross references
358 Possible Orthologues:

Solute Carrier Family 29 Member 1 (Augustine Blood Group)

Ensembl ID : ENSLCRG00005013423
Gene Symbol: SLC29A1
3 Cross references
210 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).